Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- JGM (76)
- JMG (71)
- Humans (22)
- Animals (14)
- Mice (13)
-
- Female (6)
- Gene Expression Regulation (6)
- Genome (5)
- Animal (4)
- Cell Line (4)
- Disease Models (4)
- Disease Models, Animal (4)
- Gene Expression Profiling (4)
- Xenograft Model Antitumor Assays (4)
- Base Sequence (3)
- COVID-19 (3)
- Genetic (3)
- Genomics (3)
- Knockout (3)
- Metabolomics (3)
- Mice, Knockout (3)
- RNA-Seq (3)
- Tumor (3)
- Antineoplastic Agents (2)
- Biological (2)
- Biomarkers (2)
- Brain Neoplasms (2)
- Cell Line, Tumor (2)
- Chromatin (2)
- Computational Biology (2)
Articles 151 - 151 of 151
Full-Text Articles in Medicine and Health Sciences
Lumos - Low And Intermediate Grade Glioma Umbrella Study Of Molecular Guided Therapies At Relapse: Protocol For A Pilot Study, Benjamin Y Kong, Hao-Wen Sim, Anna K Nowak, Sonia Yip, Elizabeth H Barnes, Bryan W Day, Michael E Buckland, Roel G W Verhaak, Terrance Johns, Cleo Robinson, Et Al
Lumos - Low And Intermediate Grade Glioma Umbrella Study Of Molecular Guided Therapies At Relapse: Protocol For A Pilot Study, Benjamin Y Kong, Hao-Wen Sim, Anna K Nowak, Sonia Yip, Elizabeth H Barnes, Bryan W Day, Michael E Buckland, Roel G W Verhaak, Terrance Johns, Cleo Robinson, Et Al
Faculty Research 2021
Grades 2 and 3 gliomas (G2/3 gliomas), when combined, are the second largest group of malignant brain tumours in adults. The outcomes for G2/3 gliomas at progression approach the dismal outcomes for glioblastoma (GBM), yet there is a paucity of trials for Australian patients with relapsed G2/3 gliomas compared with patients with GBM. LUMOS will be a pilot umbrella study for patients with relapsed G2/3 gliomas that aims to match patients to targeted therapies based on molecular screening with contemporaneous tumour tissue. Participants in whom no actionable or no druggable mutation is found, or in whom the matching drug is …